Dr. John Patrick Chute, MD

Dr. Chute practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Chute's NPI, 1164505319, was assigned on October 23, 2006. Dr. Chute graduated from Georgetown University School Of Medicine in 1990. Dr. Chute holds California license G86594.

Dr. Chute's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Chute's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chute practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chute's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Chute is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Chute's licenses on file in 3 states: California, North Carolina and Maryland.

CMS data shows 143 Medicare services from Dr. Chute across 1 procedure code in 2024, for 39 Medicare patients. Medicare paid $9,650 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 39 Medicare patients who saw Dr. Chute in 2024. The largest group is 65 to 74, with 20 patients. 74% of them have high blood pressure, and 74% have high cholesterol. 33% are also on Medicaid. Their average risk score is 3.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chute's median patient age at 57, with 42% women.

In 2024, Dr. Chute wrote 13 Medicare Part D claims. 85% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $65,165 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Chute for performance year 2024, reported as part of a group. Dr. Chute accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 65 papers to Dr. Chute, published from 2004 to 2024. 2017 was the busiest year, with 5. The most frequent topics are Hematopoietic Stem Cells, Hematopoietic Stem Cell Transplantation and Cells, Cultured. Dr. Chute has published most often in Biol Blood Marrow Transplant. Dr. Chute's most frequent co-authors are Joshua Parks Sasine, MD, Gwynn D. Long, MD and Vivian Yoo Jung Chang, MD.

Dmand AI links Dr. Chute to 1 clinical trial. Conditions studied include Cytomegalovirus Infections and Herpesviridae Infections.

CMS Open Payments shows 3 general payments to Dr. Chute from 2 drug and device companies from 2016 to 2017. Travel and lodging make up the largest share, 91% of the total. Pfizer Inc. paid the most, $482.

Dmand AI lists 2 awards for Dr. Chute, most recently CMS Stage 1 EHR in 2013.

Dr. Chute graduated from Georgetown University School Of Medicine in 1990.

Dr. Chute is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.